Intervention Review

You have free access to this content

Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm

  1. Lindsay Robertson1,*,
  2. Edmond Atallah2,
  3. Gerard Stansby3

Editorial Group: Cochrane Peripheral Vascular Diseases Group

Published Online: 21 JAN 2014

Assessed as up-to-date: 10 APR 2013

DOI: 10.1002/14651858.CD010447.pub2


How to Cite

Robertson L, Atallah E, Stansby G. Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD010447. DOI: 10.1002/14651858.CD010447.pub2.

Author Information

  1. 1

    Freeman Hospital, Department of Vascular Surgery, Newcastle upon Tyne, UK

  2. 2

    Mid Cheshire Hospitals NHS Foundation Trust, Leighton Hospital, Crewe, Cheshire, UK

  3. 3

    Freeman Hospital, Northern Vascular Centre, Newcastle upon Tyne, UK

*Lindsay Robertson, Department of Vascular Surgery, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, High Heaton, Newcastle upon Tyne, NE7 7DN, UK. lindsay.robertson@nuth.nhs.uk. lindsay.robertson@ed.ac.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 21 JAN 2014

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Metoprolol versus placebo, Outcome 1 All-cause mortality, 30 days.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Metoprolol versus placebo, Outcome 2 Cardiovascular death, 30 days.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Metoprolol versus placebo, Outcome 3 AAA-related death, 30 days.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Metoprolol versus placebo, Outcome 4 Nonfatal cardiovascular event, 30 days.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Metoprolol versus placebo, Outcome 5 All-cause mortality, 6 months.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Metoprolol versus placebo, Outcome 6 Cardiovascular death, 6 months.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Metoprolol versus placebo, Outcome 7 Nonfatal cardiovascular event, 6 months.